Hutch News

Hutch News

Stories tagged 'AMP study'

New 'mosaic' HIV vaccine study launched for World AIDS Day

As lights around the world glow red today, Fred Hutch-based researchers lead global effort to end the pandemic

Dec. 1, 2017 | By Mary Engel / Fred Hutch News Service

The HIV Vaccine Trials Network is having a banner year. Last month in South Africa, the network launched a clinical trial called the Imbokodo Study to test an experimental vaccine regimen designed to protect against HIV subtypes around the world. Over the coming months, the Imbokodo study will roll out in four other southern African countries.

View story >


Community-building leads to record enrollment in HIV prevention study

Fighting the stigma of HIV among communities of color takes trust — and time

Aug. 4, 2017 | By Mary Engel / Fred Hutch News Service

Vic Sorrell knows that the secret behind a successful HIV prevention study is spending the time to establish relationships and earn trust. A pioneer in community engagement, Sorrell works for the Vanderbilt HIV Vaccine Program, a unit of the Fred Hutch-based HIV Vaccine Trials Network.

View story >


Empowering ‘millions of women’ against HIV

AMP study in sub-Saharan Africa tests an antibody infusion that could put protection in women’s hands

Oct. 21, 2016 | By Mary Engel / Fred Hutch News Service

The AMP study in sub-Saharan Africa will test whether an antibody infusion protects women against HIV. If it does, the finding will have particular significance for an epidemic that hits women on that continent especially hard and for which they have few prevention options.

View story >


Renewed hope for halting HIV through vaccine

At International AIDS Conference, researchers are optimistic as two new HIV vaccine trials are set to explore different approaches for protection

July 19, 2016 | By Mary Engel / Fred Hutch News Service

At the International AIDS Conference in Durban, South Africa, researchers are optimistic as two new HIV vaccine trials are set to explore different approaches for protection.

View story >


Seattle's life sciences scene in the spotlight

Xconomy forum highlights research in vaccines, organ transplants, big data, more

May 3, 2016 | By Rachel Tompa / Fred Hutch News Service

It was a dizzying round-up of Seattle’s life sciences research and biotech scene, from designer proteins to the looming threat of the Zika virus. This year’s forum was titled “Life Sciences Disruptors,” though Lash and the other speakers didn’t focus on the technology buzzword theme, but if there was one common thread to the afternoon’s whirlwind tour of Seattle’s public and private life sciences work it was that which is new and unexpected — and a look to the future of healthcare.

View story >


A new path to an AIDS vaccine?

A ‘landmark’ clinical trial called the AMP study launches on three continents to test HIV-blocking super antibodies

April 7, 2016 | By Mary Engel / Fred Hutch News Service

“It’s not often that you know that you’re starting a landmark study," says Dr. Larry Corey, founder and director of the HIV Vaccine Trials Network. Two of the world’s top HIV prevention clinical trial networks have joined forces to test an experimental antibody that could potentially protect people from infection by almost all strains of the rapidly mutating AIDS virus.

View story >



GIVE NOW &
SAVE LIVES

Support our quest for cures

Story Archive


Publications

Hutch Magazine
Our quarterly magazine

Annual Report
Fiscal year highlights

Science Spotlight
Monthly review of Center-authored papers



Fred Hutch News

        Get updates via email.